Key Drivers
- Liquidity Cushion
- Zero Revenue
- Ongoing Cash Burn
AIAI Summary
COGT has shifted from a pipeline story to a near-term FDA-and-launch execution trade, where its strong cash runway buys time but the stock now hinges on clean approvals, early commercial traction, and avoiding dilution amid still-heavy losses and fading momentum.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Liquidity Cushion
- •Zero Revenue
- •Ongoing Cash Burn
COGT has a strong balance sheet and ample liquidity, but zero revenue, ongoing losses, and persistent cash burn make the stock highly risky.
Price Behavior
Key Price Behavior Insights:
- •Failed breakout
- •Support nearby
- •Momentum rolled over
COGT has weakened over the last month after a failed breakout and loss of the early-August advance, with near-term support in the high-$37s but resistance still overhead at $41.5-$42.8.
Failed breakout above the late-July band and full retrace of the early-August rally
Sentiment & News
Key News Insights:
- •Regulatory progress
- •Cash runway
- •Support base
Cogent Biosciences is advancing bezuclastinib toward multiple FDA decisions with a strong cash runway, while recent stock weakness may be stabilizing into a support base.
The news is modestly constructive for COGT, as pipeline and funding visibility support longer-term upside even as the shares work through near-term technical weakness
Similar Companies in Healthcare
Other companies in the same sector with AI ratings